GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Insmed Incorporated
Insmed is a biotech company focused on treating rare lung diseases. Its stock price has been a roller coaster ride, typical of biotech companies. Its sharp ups and downs are directly linked to clinical trial results and regulatory decisions.
Share prices of companies in the market segment - Specialized pharma
Insmed is a biopharmaceutical company focused on treating rare lung diseases. We classify it as a Specialized Pharma company. The chart below reflects the overall dynamics of the biotech sector, where a company's value is determined by the success of its clinical trials.
Broad Market Index - GURU.Markets
Insmed is a biopharmaceutical company focused on treating rare and serious diseases, particularly respiratory diseases. Its innovations earn it a spot on the GURU.Markets index. The chart below represents the market. See how clinical trial successes impact Insmed shares.
Change in the price of a company, segment, and market as a whole per day
INSM - Daily change in the company's share price Insmed Incorporated
Insmed is a biopharmaceutical company focused on treating rare diseases. Its daily share price fluctuations reflect the high volatility of the biotech sector. This seemingly mundane metric is an important component of the analytical formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Insmed Incorporated operates in the volatile biotech sector, focusing on rare diseases. This chart shows the average daily performance of the entire pharmaceutical industry. Comparing this to INSM shares helps us understand how the company's risks associated with the success of one key drug make it more volatile than the sector as a whole.
Daily change in the price of a broad market stock, index - GURU.Markets
Insmed is a biopharmaceutical company specializing in the treatment of rare lung diseases. Biotech focused on rare diseases is a volatile niche. The chart below shows the average fluctuations in this sector, allowing you to assess the risks and potential of Insmed shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Insmed Incorporated
Insmed is a biotech company specializing in the treatment of rare diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall flow of market movements, shaping its daily pattern.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Insmed Incorporated is a biotech company focused on treating rare lung diseases. Its success depends on the commercialization of its lead drug and the clinical trial results of its new candidates. The chart below shows how the market perceives its potential to become a leader in this complex medical niche.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Insmed is a biopharmaceutical company focused on treating rare lung diseases. Its growth depends entirely on the success of its key drug and clinical trial results. This is a classic biotech story, where a scientific breakthrough can lead to explosive growth, regardless of the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Insmed Incorporated
The market capitalization of Insmed, a biopharmaceutical company focused on rare diseases, is extremely sensitive to news. Monthly fluctuations on the chart are not a reflection of market cycles, but rather a direct reaction from investors to the results of key clinical trials and regulatory decisions that shape the company's future.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
This chart reflects the dynamics of the biotech sector. For Insmed, a late-stage company, it's the backdrop. Its movements show how the company, preparing to launch its potential blockbuster lung disease treatment, is outperforming investor expectations in a volatile sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Insmed is a biopharmaceutical company focused on treating rare lung diseases. Its value depends almost entirely on clinical trial results and regulatory approvals. Overall market performance has little impact on Insmed shares; their fate is decided in laboratories and FDA offices, which can lead to sharp movements counter to any market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Insmed Incorporated
Insmed, a biopharmaceutical company focused on rare diseases, is highly volatile. Its weekly stock price reflects news about clinical trials, regulatory decisions, and scientific publications. The chart clearly demonstrates how expectations of a breakthrough influence the stock price.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Insmed, a biopharmaceutical company focused on rare diseases, often moves in tandem with overall sentiment in the biotech sector. The chart compares its volatility with the industry's, distinguishing between reactions to general sector news and sharp movements driven by Insmed-specific clinical trial news.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Insmed is a biotech company focused on treating rare lung diseases. Its shares follow their own rhythm, driven by clinical trial results. The chart shows how independent Insmed's performance is from general market fluctuations, driven by its own unique news.
Market capitalization of the company, segment and market as a whole
INSM - Market capitalization of the company Insmed Incorporated
The Insmed chart is a map of hope in the fight against rare lung diseases. Its market cap reflects not current sales, but investors' faith in the potential of its scientific developments to become a new standard of treatment. Every rise on this chart is a response to successful clinical trials, bringing hope to thousands of patients.
INSM - Share of the company's market capitalization Insmed Incorporated within the market segment - Specialized pharma
Insmed is a biotech company focused on treating rare diseases, particularly pulmonary diseases. Its market capitalization in the specialty pharmaceuticals niche reflects the potential of its drugs and investors' confidence in the success of its developments. The chart below shows how the market assesses its chances of becoming a leader in its narrow but important field.
Market capitalization of the market segment - Specialized pharma
Insmed focuses on treating rare diseases, a high-risk but potentially highly profitable niche. The chart below shows the overall market capitalization of the entire specialty pharmaceuticals segment. Its dynamics reflect investors' faith in biotech breakthroughs and their willingness to fund long-term development.
Market capitalization of all companies included in a broad market index - GURU.Markets
Fighting rare diseases is not only a medical challenge, but also an economic one. The Insmed chart shows how a biotech company focused on orphan diseases creates value that stands out from the rest of the market. It's a story of how breakthrough science turns into a multibillion-dollar business.
Book value capitalization of the company, segment and market as a whole
INSM - Book value capitalization of the company Insmed Incorporated
The book value of Insmed, a biopharmaceutical company, reflects its investments in the future. The graph shows not so much its factories as the capital invested in expensive research and development. The growth of this line shows how the company is building the scientific and financial foundation for the development of new drugs.
INSM - Share of the company's book capitalization Insmed Incorporated within the market segment - Specialized pharma
Insmed is focused on treating rare diseases. Its value lies in its patents and research, but producing innovative drugs requires specialized laboratories and factories. The asset share chart shows how the company is investing in the unique physical foundation for creating breakthrough drugs.
Market segment balance sheet capitalization - Specialized pharma
Against the backdrop of the capital-intensive pharmaceutical industry with its gigantic factories, Insmed has chosen a niche path. The company focuses on rare diseases, and its value lies in its intellectual property. The graph illustrates the material strength of the industry, while Insmed builds its success on science, not on production scale.
Book value of all companies included in the broad market index - GURU.Markets
Insmed fights rare lung diseases, and its assets are more than just laboratories; they represent hope for thousands of patients. These assets represent capital invested in cutting-edge science and the development of unique medicines. The chart shows the financial resources concentrated in the hands of this company solving the most complex medical problems.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Insmed Incorporated
Insmed Incorporated is a biopharmaceutical company. Its high market capitalization relative to its assets is a pure bet on its lead drug for a rare lung disease. The chart shows the huge premium investors are paying for this blockbuster's potential.
Market to book capitalization ratio in a market segment - Specialized pharma
Insmed Incorporated is a biotech company focused on treating rare diseases. Its main assets are not its laboratories, but patents and clinical trial results. This chart shows how the market valuation, based on the expected success of future drugs, is many times greater than the company's modest book value.
Market to book capitalization ratio for the market as a whole
Insmed is a biotech company focused on treating rare diseases. It may not have large manufacturing facilities, but its greatest asset is its patents for unique drugs and promising developments in its portfolio. The chart clearly demonstrates how the market values this intellectual capital, giving the company a valuation that is multiples of its book value.
Debts of the company, segment and market as a whole
INSM - Company debts Insmed Incorporated
Biotech company Insmed's debt strategy is focused on funding breakthrough research. The company raises funds to conduct costly clinical trials of drugs for rare lung diseases. This chart shows how Insmed uses capital to achieve the scientific goals that shape its future.
Market segment debts - Specialized pharma
Insmed is a biotech company focused on treating rare diseases. Its financial structure is typical for the industry: the company can raise significant debt to finance multi-year, expensive clinical trials. This chart helps understand the company's stage of development and how its debt load compares to sector risks.
Market debt in general
Insmed Incorporated is a biopharmaceutical company focused on treating rare diseases. In biotech, where the path from development to commercialization is long and expensive, financial management is critical. This chart provides insight into the overall investment climate in which Insmed raises capital for clinical trials, balancing risk with breakthrough potential.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Insmed Incorporated
Biopharmaceutical company Insmed focuses on rare diseases, which require lengthy and expensive clinical trials. This chart shows how the company finances its research. A high level of leverage may indicate lenders' confidence in the success of its drugs, but it also suggests high risks if the trials don't meet expectations.
Market segment debt to market segment book capitalization - Specialized pharma
Insmed Incorporated focuses on treating rare diseases, which requires significant investment in R&D. This chart reflects the debt policy in the specialty pharmaceuticals niche. It shows how companies in the sector finance lengthy and risky research and allows one to evaluate Insmed's financial strategy against its innovative competitors.
Debt to book value of all companies in the market
Insmed Incorporated is a biopharmaceutical company focused on rare diseases. This chart shows the overall debt level across the market. It allows one to compare Insmed's financial model, which requires massive investments in R&D with uncertain outcomes, with the more conservative debt policies of established companies in the general economy.
P/E of the company, segment and market as a whole
P/E - Insmed Incorporated
This chart for Insmed Incorporated illustrates the complex task of valuing a biotech company focused on rare diseases. Often, such companies do not yet have stable profits. Therefore, this metric can be extremely high or absent, reflecting not current revenue but rather investors' enormous expectations for the potential future success of their drugs.
P/E of the market segment - Specialized pharma
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly respiratory disorders. The company operates at the forefront of science. This chart shows the average valuation in the specialty pharmaceutical niche, reflecting investor expectations for companies pursuing innovative but risky developments.
P/E of the market as a whole
Insmed is a biopharmaceutical company focused on treating rare diseases. Its value depends not on economic cycles, but on clinical trial success and regulatory approvals. This chart shows the overall market "temperature." Comparison with it reveals how Insmed's valuation is detached from market realities and relies solely on hopes for a scientific breakthrough.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Insmed Incorporated
Insmed is a biopharmaceutical company focused on treating rare diseases, particularly in pulmonology. This chart shows the company's future prospects. It is based almost entirely on expectations for clinical trials and the commercial success of its key drugs, making the indicator's performance highly sensitive to laboratory news.
%20P%2FE%20Insmed%20Incorporated&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Insmed-Incorporated&v=1772600007296 "Chart of the company's future (projected) P/E Insmed Incorporated")
Future (projected) P/E of the market segment - Specialized pharma
Insmed is a biopharmaceutical company focused on treating rare lung diseases. This chart compares the company's future profitability expectations with the sector average. It reflects the market's confidence that their blockbuster drugs will deliver higher revenue growth than other specialty pharma companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772600007317 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Insmed is a biopharmaceutical company focused on treating rare diseases. Its success is less dependent on general economic cycles, as reflected in this chart. Insmed's value is determined by the results of clinical trials. The chart merely reflects the overall risk appetite of investors, which influences the availability of capital for such innovative companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772600007350 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Insmed Incorporated
Insmed is a biopharmaceutical company focused on treating rare diseases, particularly pulmonary diseases. Its financial results depend on the success of clinical trials, regulatory approval, and the commercial launch of its drugs. This chart illustrates the complex and risky path from scientific development to stable profitability in the biotech sector.
Profit of companies in the market segment - Specialized pharma
Insmed is a biopharmaceutical company focused on treating serious and rare diseases, particularly pulmonary infections. This chart shows profitability in the specialty pharmaceuticals sector. The company's success depends on its ability to successfully commercialize its drugs and continue research in niche but critical areas of medicine.
Overall market profit
Insmed is a biopharmaceutical company focused on treating rare diseases. Its success depends less on the general economic cycles visible on the chart than on the results of clinical trials and drug approvals by regulators. This makes its shares potentially unaffected by macroeconomic trends but dependent on scientific breakthroughs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Insmed Incorporated
Insmed is a biotech company focused on treating rare diseases, particularly lung diseases. This chart reflects analysts' forecasts for future profits, which depend entirely on the commercial success of its drugs and progress in clinical trials. Positive news from the labs can dramatically change market expectations for future revenue.
%20profit%20of%20the%20company%20Insmed%20Incorporated&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Insmed-Incorporated&v=1772600007627 "Graph of future (projected) profit of the company Insmed Incorporated")
Future (predicted) profit of companies in the market segment - Specialized pharma
Insmed is a biopharmaceutical company focused on treating rare diseases, particularly pulmonary diseases. This chart reflects profitability expectations for the specialty pharmaceuticals niche. It helps understand how the market perceives the potential of new treatments for rare diseases and the willingness of healthcare systems to pay for innovative drugs, which is important for assessing Insmed's future.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772600007708 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Insmed Incorporated is a biopharmaceutical company focused on treating rare diseases. Its success is less dependent on the short-term economic cycles illustrated here. However, the overall market situation influences the cost of capital and investor sentiment, which is important for funding the lengthy and expensive clinical trials required to develop new drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772600007736 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Insmed Incorporated
Insmed is a biotech company focused on treating rare and serious lung diseases. Because the company is in the growth and product launch phase, its revenue can be volatile. This chart is useful for assessing how investors view its current and future sales, based on their belief in the potential of its unique drug candidates.
P/S market segment - Specialized pharma
Insmed is a biopharmaceutical company focused on treating rare diseases, particularly pulmonary diseases. Valuations of such companies often outpace current revenue due to expectations of future breakthroughs. This chart shows the average valuation for the sector, which helps us understand the premium the market is pricing into Insmed for innovation and the potential of future drugs.
P/S of the market as a whole
Insmed is a biopharmaceutical company focused on treating rare diseases, particularly in pulmonology. Its success depends on the results of clinical trials and the commercialization of unique drugs. This overall market valuation chart helps understand the premium investors are willing to pay for the potentially high but risky revenue potential of biotech compared to stable sectors.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Insmed Incorporated
Insmed is a biopharmaceutical company focused on treating rare diseases, particularly pulmonary diseases. Its future revenue depends on the success of clinical trials and the commercialization of its drugs. This chart reflects investor confidence in the potential of its developments and future sales volume following regulatory approvals.
%20P%2FS%20Insmed%20Incorporated&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Insmed-Incorporated&v=1772600007964 "The graph of the company's future (projected) P/S Insmed Incorporated")
Future (projected) P/S of the market segment - Specialized pharma
Insmed is a biopharmaceutical company focused on treating rare and serious diseases, particularly pulmonary diseases. Its value is determined by the success of clinical trials and the potential of its drug candidates. This chart reflects the market's high sales expectations, typical of biotech companies with breakthrough but risky developments.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772600007980 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Insmed is a biotech company focused on rare diseases. Its success is less dependent on general economic cycles and more dependent on investor risk appetite. The optimism shown in this chart creates a favorable environment for funding biotech research and increases the market's willingness to pay for innovative drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772600008016 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Insmed Incorporated
Insmed is a biopharmaceutical company focused on treating rare diseases, particularly pulmonary diseases. Its revenue is generated by sales of its key drug for patients with serious infections. This chart shows the commercial success of its product, reflecting the company's ability not only to develop but also to commercialize life-saving, niche drugs.
Sales of companies in the market segment - Specialized pharma
Insmed is a biopharmaceutical company focused on treating rare diseases, particularly orphan lung diseases. Its revenue is currently generated primarily from sales of a single key drug designed to combat non-tuberculous mycobacterial infections. This chart illustrates the dynamics of a niche pharmaceutical market, where success depends on innovation and regulatory approval.
Overall market sales
Insmed is a biopharmaceutical company focused on treating rare diseases. Its success depends less on short-term economic cycles, as shown in this chart, and more on the success of clinical trials. However, the overall economic situation affects the willingness of healthcare systems to pay for expensive innovative drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Insmed Incorporated
Insmed is a biopharmaceutical company focused on treating rare lung diseases. Its commercial success depends on the approval and successful launch of new drugs, as well as patient growth. This chart reflects analyst consensus sales forecasts for the company's key drugs, based on clinical trial data and market potential.
%20sales%20of%20the%20company%20Insmed%20Incorporated&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Insmed-Incorporated&v=1772600008120 "Schedule of future (projected) sales of the company Insmed Incorporated")
Future (projected) sales of companies in the market segment - Specialized pharma
Insmed is a biopharmaceutical company specializing in the treatment of rare and serious diseases, particularly in pulmonology. This chart shows projected revenue for the specialty pharmaceuticals niche. It helps understand how successful launches of Insmed's key drugs could enable it to outperform the sector average.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772600008125 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Insmed Incorporated, a biotech company focused on rare diseases, is indirectly affected by the overall economic health, as reflected in this chart. Rising market expectations indicate the stability of healthcare systems and their willingness to invest in expensive but life-saving drugs, which is critical to the commercial success of Insmed's innovative drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772600008136 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Insmed Incorporated
Insmed is a biopharmaceutical company focused on treating rare diseases. Their financial success depends on the success of clinical trials and the commercialization of highly specialized drugs. This graph illustrates the complex path from massive investments in R&D to potentially high profitability upon approval and successful market launch.
Market segment marginality - Specialized pharma
Insmed is a biopharmaceutical company focused on treating rare diseases, particularly lung infections. This chart shows how successfully the company commercializes its drugs compared to other biotech companies. High profitability in this niche demonstrates the uniqueness of its therapy and strong patent protection.
Market marginality as a whole
Insmed is a biopharmaceutical company focused on treating rare diseases. Its success depends on clinical trial results and regulatory approvals, not on general economic cycles. This chart allows investors to see how growth stocks like Insmed can perform independently of overall market returns.
Employees in the company, segment and market as a whole
Number of employees in the company Insmed Incorporated
Insmed is a biotech company focused on treating rare diseases. This chart tells the story of its transformation from a research firm to a commercial one. A rapid increase in personnel, particularly in sales and marketing, typically precedes or accompanies the launch of a new drug, a critical moment for assessing its future success.
Share of the company's employees Insmed Incorporated within the market segment - Specialized pharma
Insmed is a biopharmaceutical company focused on treating rare and orphan diseases. This indicator reflects its weight in a highly specialized niche through its talent pool. It shows the share of the best scientists and clinicians in this field that Insmed attracts to combat serious illnesses, where every specialist counts.
Number of employees in the market segment - Specialized pharma
Insmed Incorporated is a biopharmaceutical company focused on treating rare diseases, particularly in pulmonology. This chart shows the employment dynamics in the specialty pharmaceutical industry. The growing number of researchers and clinicians in this segment indicates progress in the fight against orphan diseases, where Insmed strives to become a leader.
Number of employees in the market as a whole
Insmed Incorporated is a biotech company focused on treating rare diseases. Its success depends on investments in healthcare. This chart, reflecting the state of the labor market, indicates overall economic confidence. During periods of stability, governments and insurance companies are more willing to fund expensive treatments for orphan diseases, which is critical for Insmed.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Insmed Incorporated (INSM)
Insmed is a biopharmaceutical company focused on treating rare diseases. The high capitalization per employee, which can be seen in this chart, is typical of successful biotech companies. The market values not personnel but the potential of intellectual property—patents for unique drugs that could generate billions in revenue in the future.
%20of%20the%20company%20Insmed%20Incorporated%20(INSM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Insmed-Incorporated-INSM&v=1772600008497 "Chart of market capitalization per employee (in thousands of dollars) of the company Insmed Incorporated (INSM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Insmed is a biotech company focused on rare lung diseases. Its value comes from its R&D pipeline and its hopes for future blockbusters. This chart shows the (often volatile) market value the market assigns to each employee, betting on the success of their research rather than current sales.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772600008518 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Insmed Incorporated is a biopharmaceutical company focused on treating rare diseases. Its value lies in its unique scientific developments and intellectual property. This chart shows a high market valuation per employee, reflecting the potential of their R&D platform and future cash flows from innovative drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772600008528 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Insmed Incorporated (INSM)
Insmed is a biopharmaceutical company focused on treating rare diseases. In this business, years of R&D can lead to the creation of a single breakthrough drug. This metric demonstrates how the company monetizes its intellectual capital. After the launch of a successful drug, profit per employee can increase sharply, reflecting the high margins of niche drugs rather than the labor involved in production.
%20Chart%20Insmed%20Incorporated%20(INSM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Insmed-Incorporated-INSM&v=1772600008534 "Company Profit Per Employee (in thousands of dollars) Chart Insmed Incorporated (INSM)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Insmed is a biopharmaceutical company focused on rare lung diseases. This chart shows the benchmark for "specialized pharma." In this sector (orphan and rare diseases), labor profitability is exorbitant. Monopolistic companies in their niche set very high drug prices, which sets an astronomical benchmark.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772600008546 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Insmed Incorporated is a biopharmaceutical company focused on treating rare diseases. Its value lies not in mass production, but in unique scientific developments and patents. This chart demonstrates a business model in which a small team of highly skilled scientists and researchers can create enormous value by solving complex medical problems.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772600008588 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Insmed Incorporated (INSM)
Insmed Incorporated is a biopharmaceutical company focused on treating rare diseases. This chart illustrates the specifics of its business. Revenue per employee can fluctuate significantly depending on the success of clinical trials and the launch of expensive blockbuster drugs intended for a narrow group of patients.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Insmed-Incorporated-INSM&v=1772600008662 "Sales chart per company employee Insmed Incorporated (INSM)")
Sales per employee in the market segment - Specialized pharma
Insmed is a biotech company focused on developing drugs for rare and serious lung diseases. Their core business is pure R&D and bringing breakthrough drugs to market. This chart shows the industry average per employee income. It helps assess the commercial viability of Insmed's research and development efforts.
Sales per employee for the market as a whole
Insmed is a biotech company focused on treating rare and severe diseases, particularly pulmonary diseases. Their business is focused on pure R&D and commercialization of highly specialized drugs. This metric reflects how their team of scientists and doctors creates and commercializes products with very high added value for niche patient groups.
Short shares by company, segment and market as a whole
Shares shorted by company Insmed Incorporated (INSM)
Insmed is a biopharmaceutical company focused on treating rare diseases, particularly lung diseases. It's a risky business, where everything hinges on the success of clinical trials. This chart shows the number of short positions. Investors short the stock in anticipation of key trials failing, the FDA denying approval, or a weak commercial launch.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Insmed-Incorporated-INSM&v=1772600008748 "Short Shares Chart for the Company Insmed Incorporated (INSM)")
Shares shorted by market segment - Specialized pharma
Insmed (INSM) is a biopharmaceutical company focused on treating rare lung diseases, particularly non-tuberculous mycobacterial infections. This chart shows the bet against the entire biotech segment. The rising price reflects investor fears of clinical trial failures or skepticism about the commercial potential of niche drugs, which is vital for Insmed.
Shares shorted by the overall market
Insmed is a biopharmaceutical company focused on treating rare diseases, particularly lung diseases. This is a risky sector, where success depends on clinical trial results. When this chart shows rising fear, investors avert risk. Biotech companies that haven't yet achieved stable profitability, like Insmed, often come under intense pressure, as their future earnings are heavily discounted.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Insmed Incorporated (INSM)
Insmed is a biotech focused on rare lung diseases. Its fate hinges on one or two drugs. This chart measures momentum. "Overbought" (above 70) indicates investor euphoria following the publication of breakthrough Phase 3 data or FDA approval. "Oversold" (below 30) is catastrophic: panic over an R&D failure or a drug recall, which puts the entire company's future in doubt.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Insmed-Incorporated-INSM&v=1772600008771 "RSI 14 indicator chart for the company's stock Insmed Incorporated (INSM)")
RSI 14 Market Segment - Specialized pharma
Insmed is a biotech company focused on treating rare lung diseases such as MAC. The RSI_14_Seg for "Specialized Pharma" reflects the overall sentiment in biotech. The chart helps us understand: is INSM's volatility a reaction to its clinical trials, or is the entire biotech sector overheated (or oversold)?
RSI 14 for the overall market
Insmed Incorporated is a biotech company focused on treating rare diseases (orphan diseases). It's a classic example of a high-risk sector where success depends on clinical trial data. This chart shows the overall market sentiment. During periods of panic (oversold conditions), investors are less inclined to take risks, and funding for biotechs dries up, which hits stocks like INSM hard.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast INSM (Insmed Incorporated)
Insmed is a biotech company focused on developing drugs for the treatment of rare (orphan) lung diseases. Its future depends on the success of clinical trials and regulatory approvals. This chart reflects the analysts' collective assessment of the success rate of its key drug, Arikayce, and the potential of other developments in the pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-INSM-Insmed-Incorporated&v=1772600008805 "A chart showing analyst consensus forecasts for the expected stock price. INSM (Insmed Incorporated)")
The difference between the consensus estimate and the actual stock price INSM (Insmed Incorporated)
Insmed is a biotech company focused on treating rare and serious lung diseases, such as NTM infections. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the success of its R&D pipeline and the commercial potential of its blockbuster drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-INSM-Insmed-Incorporated&v=1772600008826 "A chart showing the difference between the consensus forecast and the actual stock price. INSM (Insmed Incorporated)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Insmed is a biotech company focused on developing drugs for rare and serious diseases, particularly pulmonary diseases. This chart shows analysts' overall expectations for the specialty pharmaceutical sector. It reflects whether experts believe in the success of biotech companies' R&D pipelines.
Analysts' consensus forecast for the overall market share price
Insmed is a biopharmaceutical company focused on treating rare diseases, particularly lung diseases. Their business is driven by science, innovation, and a long clinical trial pipeline. This chart shows the overall market sentiment. For Insmed, as for many biotechs, it's important how overall sentiment influences investor appetite for risk, which is necessary to fund their research. (348)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Insmed Incorporated
Insmed is a biotech company focused on treating rare and serious diseases, primarily in pulmonology (lung disease). This graph represents a classic biotech valuation. It depends almost entirely on the progress of their clinical trials, regulatory approvals (FDA), and the market potential of their key drug candidates.
AKIMA Market Segment Index - Specialized pharma
Insmed is a biotech company focused on treating rare and serious lung diseases, such as NTM infections. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Insmed's niche strategy and its R&D pipeline (Arikayce) differentiate it from the average pharma company?
The AKIM Index for the overall market
Insmed is a biotech company focused on treating rare and severe lung diseases. Its success depends on the approval and adoption of its innovative drugs. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story, driven by the laws of biotech, compares to general economic trends that influence investor risk appetite.
